Claudia Pagenkopf1, Martin Südmeyer2. 1. Klinikum Ernst von Bergmann, Department of Neurology, Charlottenstrasse 72, 14467 Potsdam, Germany. Electronic address: claudia.pagenkopf@klinikumevb.de. 2. Klinikum Ernst von Bergmann, Department of Neurology, Charlottenstrasse 72, 14467 Potsdam, Germany; Department of Neurology, Medical Faculty, University Düsseldorf, Düsseldorf, Germany. Electronic address: martin.suedmeyer@klinikumevb.de.
Abstract
BACKGROUND: Longitudinally extensive transverse myelitis (LETM) is a rare subtype of transverse myelitis (TM) that potentially results in relevant disability. Apart from association to neuromyelitis optica and other chronic demyelinating diseases of the central nervous system, many other aetiologies are known. Particularly systemic infections and vaccination are considered potential triggers for immune mediated inflammation of the spinal cord. In the course of the current Covid-19 pandemic several cases of TM following Covid-19 infection have been described. Here we present a case of LETM following vaccination against Covid-19 with AZD1222, AstraZeneca. An extensive diagnostic work up was performed to rule out alternative causes, including prior and current Covid-19 infection. CONCLUSION: To our knowledge this is first case of LETM possibly related to Covid-19 vaccination that is published after marketing authorisation of various vaccine candidates.
BACKGROUND:Longitudinally extensive transverse myelitis (LETM) is a rare subtype of transverse myelitis (TM) that potentially results in relevant disability. Apart from association to neuromyelitis optica and other chronic demyelinating diseases of the central nervous system, many other aetiologies are known. Particularly systemic infections and vaccination are considered potential triggers for immune mediated inflammation of the spinal cord. In the course of the current Covid-19 pandemic several cases of TM following Covid-19infection have been described. Here we present a case of LETM following vaccination against Covid-19 with AZD1222, AstraZeneca. An extensive diagnostic work up was performed to rule out alternative causes, including prior and current Covid-19infection. CONCLUSION: To our knowledge this is first case of LETM possibly related to Covid-19 vaccination that is published after marketing authorisation of various vaccine candidates.